Business
Supporting the Dementias Research Platform UK
Supporting the Dementias Research Platform UK.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 6444V Cambridge Cognition Holdings PLC 30 October 2014 \n \n\n \n \nCambridge Cognition Holdings Plc\n(\"Cambridge Cognition\" or the \"Company\")\n \nSupporting the Dementias Research Platform UK\n \nCambridge Cognition, (AIM: COG), which specialises in computerised neuropsychological tests, announces that the Company strongly supports the launch of The Medical Research Council ('MRC') Dementias Research Platform UK ('DPUK'). Cambridge Cognition's Cantab Connect is playing a significant role in the ongoing DPUK Dementia Deep and Frequent Phenotyping feasibility study.\n \nThis joint-funded National Institute for Health Research ('NIHR') and MRC project for intensive phenotyping of 24 pre-clinical Alzheimer's disease patients, aims to identify biomarkers that change over periods of months, rather than years. The Deep and Frequent Phenotyping study assesses key cognitive domains affected in Alzheimer's disease using Cambridge Cognition's rapid touchscreen cognitive test system, Cantab Connect.\n \nAlongside the cognitive tests, the study uses an extensive range of MR imaging, additional clinical testing and biomarkers, at frequent intervals during the three months study period for each participant. The goal is to identify protocols and biomarkers that will be used in a wide range of follow-on trials\n \nThe MRC DPUK is a £53m public-private partnership with World leading researchers from Universities across the UK (Cambridge, Cardiff, Edinburgh, Imperial College, Oxford, Manchester, Newcastle, Swansea and UCL) and six companies (GlaxoSmithKline, Janssen Research & Development, AstraZeneca-MedImmune, Ixico, SomaLogic and Araclon) who will use state of the art technologies such as Cantab Connect to accelerate progress in dementias research. It brings together two million participants aged 50 and over, from 22 existing study groups within the UK, making it the World's largest population study for use in dementias research. The DPUK's aims are early detection, improved treatment and ultimately, prevention, of dementias.\n \nDr Jenny Barnett, Director of Healthcare Innovation at Cambridge Cognition commented: \"We fully support the DPUK initiative and are pleased to see the UK setting a leading example to accelerate early detection of dementia and develop knowled...